20 November 2026
by Joanne S. Eglovitch

Final ICH Q1 stability testing guideline expected to be released soon

ICH_Logo_260608_ICH.jpg 1
(Source: ICH)

The pending revision of the International Council for Harmonization (ICH) Q1 guideline on stability testing has been adopted and is expected to be published “in the coming weeks,” according to a 19 November announcement from the council. Once published, it will be classified as a Step 4 guideline and will be ready for regulatory implementation.

ICH made this recent announcement following a meeting of its biannual assembly held in Prague.

The updated guideline will replace seven existing guidelines, specifically the ICH Q1A-Q1F series and ICH Q5.  The original ICH Q1A guideline, which covers basic stability testing, was first released in 1993 and was one of the first harmonized guidance documents issued by the ICH. Over time, the ICH Q1A guideline has evolved to include additional topics, such as photostability testing (ICH Q1B), new dosage form stability (ICH Q1C), bracketing and matrixing designs for tests (ICH Q1D), and applications of stability testing for climatic zones III and IV (ICH Q1F).

A draft Step 2 guideline was published on 17 April 2025 (RELATED: ICH releases overhauled stability guideline for consultation, Regulatory Focus 17 April 2025).

In its announcement, ICH also emphasized the urgent need for its members to implement M8, the Electronic Common Technical Document (eCTD) version 4. The group said this implementation is critical for modernizing global regulatory submissions.

ICH M8 outlines the electronic submission format and the technical specifications for the eCTD. The ICH has stated that companies must adopt eCTD version 4.0 before the rollout of ICH M4Q(R2), which defines the content and organization of the eCTD. The ICH expects M4Q(R2) to be finalized by 2027.

In the EU, eCTD submissions in Version 4 will become mandatory for all centrally authorized products in 2027. The FDA will require mandatory eCTD submissions in version 4 by 2029.

During a meeting earlier this year, officials from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) urged companies to intensify their efforts to test their eCTD version 4.0 before it becomes mandatory (RELATED: FDA, EMA officials encourage companies to pilot eCTD 4.0, Regulatory Focus 3 February 2026).

ICH members also reported progress on various guidelines related to efficacy, safety, and multidisciplinary areas.

In the safety sector, ICH has endorsed the draft guideline S13 for the nonclinical safety evaluation of oligonucleotide-based therapeutics. The guideline was released for public comment on 18 November.

In the efficacy area, the Expert Working Group for E24 released a concept paper on natural history studies and patient registries to advance drug development for rare diseases. The paper was released on 15 November 2026.

Additionally, the group approved a question-and-answer document under the ICH E14/S7B titled “Questions & Answers (R1): Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential, " which received approval in August 2026.

In the multidisciplinary area, the ICH M13B guideline entitled “Bioequivalence for Immediate Release Solid Oral Dosage Forms: Additional Strengths Biowaiver” was approved on 4 August 2026.

ICH plans to launch its fourth implementation survey at the end of 2026, which is expected to shed some light on the status of ICH guideline implementation. The results are anticipated to be available by mid-2027.

Additionally, the group released MedDRA Version 29.1, which is now available in 28 languages, including the newly added Romanian translation.

Two new regulators joined as members: Hong Kong China’s Pharmacy and Poisons Board (PPBHK) and  El Salvador’s Superintendence of Sanitary Regulation (SRS). Three new countries joined as observers: Oman’s Ministry of Health (MOH), the United Arab Emirates’ Drug Establishment (EDE), and Zimbabwe’s Medicines Control Authority (MCAZ). The total number of ICH members is 27, and the number of observers is 44.

The next ICH biannual meetings are scheduled for 13 June 2027, in Madrid and 14 November 2027, in Paris.

Announcement